China Resources Double-Crane Pharmaceutical Company Limited (CR Double-Crane) boasts a proud history of 87 years. It was originally established as a military pharmaceutical factory in 1939 referred to as Li Hua Pharmaceutical Factory in Taihang. In 1949, after relocating with the military to Beijing, the first state-owned chemical pharmaceutical factory was established, later renamed Beijing Pharmaceutical Factory. This laid the foundation for the modern chemical pharmaceutical industry in Beijing. In 1997, the company integrated high-quality assets and established Double-Crane Pharmaceutical, which got listed on the Shanghai Stock Exchange. Through external expansion, it evolved into a Beijing-based multi-regional group, with a nationwide presence. In 2010, it became part of China Resources (Holdings) Company Limited, one of the world’s top 500 companies. In 2012, the company was renamed CR Double-Crane, now serving as the pharmaceutical business platform in the healthcare sector of China Resources (Holdings) Company Limited.
The company currently has 24 subsidiaries and 13,000 employees. Its main business encompasses new drug research and development, formulation production, pharmaceutical sales, active pharmaceutical ingredient (API) production, and pharmaceutical equipment. The company boasts a rich product line, brand advantages, high product quality, effective cost control, a robust channel and terminal coverage, strong management capabilities, international advantages, a dynamic team, and strong cultural heritage. In 2025, it achieved a revenue of 11 billion RMB and a net profit of 1.68 billion RMB. Its overall strength and R&D capabilities rank 14th in the industry. The company holds over 2,000 drug approvals, with more than 330 products currently in production and sale. It has a strong presence in key therapeutic areas such as chronic diseases, infusion, pediatrics, nephrology, psychiatry/neurosciences, oncology, and women’s health, maintaining a leading market position in several niche sectors. Additionally, 25 products generate annual sales exceeding 100 million RMB.
As the company develops, it adheres to the strategic philosophy of “nurturing innovation through generics and driving the future with innovation.” With a dual approach of R&D innovation and external development, CR Double-Crane is advancing its operational excellence. The company is accelerating its transformation into R&D innovation, with over 200 ongoing research projects. It is speeding up the construction of 11 key technology platforms, and in recent years, more than 100 generic drugs have been approved. The company’s innovation pipeline has taken shape, with 15 innovative drug projects, including 2 small-molecule self-research projects that have been approved for clinical trials. It closely follows national strategic directions and actively ventures into emerging fields such as synthetic biology. CR Double-Crane is establishing a three-tier system for R&D, pilot testing, and industrialization, with 10 projects in its reserve and undertakes major national special projects, contributing its capabilities to meet national needs. The company has first-class domestic manufacturing and production capabilities. It operates 23 production bases across 15 provinces and cities in China, establishing an advanced production and quality management system while promoting intelligent manufacturing and green production. The company is actively embracing centralized procurement and deepening the transformation of its marketing model. Its sales network covers all 33 provinces, municipalities, autonomous regions, and special administrative regions in China, with strong influence in the North China, Jiangsu-Zhejiang, and infusion base markets. Its foreign trade business, primarily focused on APIs, generates a revenue of approximately 700 million RMB, with over 50 product varieties covering more than 50 countries worldwide. CR Double-Crane maintains good partnerships with leading pharmaceutical companies in several countries. The company has integrated information technology and digitalization across its entire business chain, creating a new industrial development model powered by information technology as a new capability and engine.
Looking to the future, the company will continue to uphold its founding mission of “serving people’s health,” accelerate the promotion of high-quality development, and strive to become a trusted, innovation-driven, world-class pharmaceutical enterprise, making even greater contributions to public health and the industry’s growth.
